NCT00306553View on ClinicalTrials.gov

Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
Malignant Melanoma
Interventions
BIOLOGICAL

CYT004-MelQbG10

Trial Locations (2)

8091

Dept. of Dermatology, USZ, Zurich

Dept. of Oncology, USZ, Zurich

Sponsors
All Listed Sponsors
lead

Cytos Biotechnology AG

INDUSTRY

NCT00306553 - Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients | Biotech Hunter | Biotech Hunter